Variants for PFS HR 95% CI P
ECOG-PS (≥2 vs. 0/1) 1.13 0.79­–1.61 0.52
BMI (< 18.5 vs. ≥ 18.5) 1.78 1.28–2.50 < 0.001*
Number of organs involved as metastatic lesions (≥ 2 vs. 0/1) 1.22 0.89–1.68 0.21
EGFR mutation status (Exon 21 L858R vs. Exon 19 del) 1.05 0.77–1.43 0.78
EGFR mutation status (Other vs. Exon 19 del) 2.59 1.51–4.45 < 0.001*
GRIm score (High vs. Low) 1.94 1.27–2.97 0.0023*
Concomitant medications (≥5 vs. ≤ 4) 1.34 0.99–1.82 0.056
Variants for OS HR 95% CI P
Age group (≥ 75 vs. 65-74) 1.57 1.12–2.21 0.017*
ECOG-PS (≥2 vs. 0/1) 1.54 1.06–2.25 0.024*
BMI (< 18.5 vs. ≥ 18.5) 1.86 1.29–2.67 < 0.001*
Number of organs involved as metastatic lesions (≥ 2 vs. 0/1) 1.60 1.13–2.26 0.0079*
EGFR mutation status (Exon 21 L858R vs. Exon 19 del) 1.13 0.79–1.60 0.50
EGFR mutation status (Other vs. Exon 19 del) 1.91 1.08–3.39 0.026*
Osimertinib use in clinical course (Yes vs. No) 0.44 0.27–0.71 < 0.001*
GRIm score (High vs. Low) 2.37 1.53–3.67 < 0.001*
Concomitant medications (≥5 vs. ≤ 4) 1.58 1.13–2.21 0.0076*